Generation Bio Co.(GBIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,848 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
GBIO Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Generation Bio Co. (GBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GBIO at 5.5/100 on a 32-signal composite quality model, placing it at rank #2,848 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.1) and institutional flow (1.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2025), Generation Bio Co. reports quarterly revenue of $1.6M, net income of $-5.5M, free cash flow of $-52.7M. Top institutional holders of GBIO by reported 13-F value include Atlas Venture Life Science Advisors,, SymBiosis Capital Partners,, Opaleye Management, based on the most recent SEC filings. GBIO trades on the Nasdaq exchange and files with the SEC under CIK 1733294. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Generation Bio Co. directly from SEC EDGAR. Generation Bio Co.'s 13F Pro composite quality score has ranged between 6 and 29 since 2024, currently 5.5 — a declining long-term trajectory across 16 quarterly and live scoring snapshots.
Revenue
Q3 2025
$1.6M
Net Income
Q3 2025
$-5.5M
Free Cash Flow
Q3 2025
$-52.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+236.9% YoYNet Income
-4.0% YoYOperating Income
-2.8% YoYEPS (Diluted)
-1.0% YoYTotal Assets
-38.3% YoYOp. Cash Flow
-67.9% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Revenue | $19.9M +236.9% | $5.9M | $0.00 | — | — |
| Net Income | $-131.7M -4.0% | $-126.6M +7.3% | $-136.6M -69.7% | $-80.5M -31.4% | $-61.3M |
| Operating Income | $-142.4M -2.8% | $-138.6M +1.9% | $-141.2M -74.1% | $-81.1M -30.2% | $-62.3M |
| EPS (Diluted) | $-1.98 -1.0% | $-1.96 +16.6% | $-2.35 +20.3% | $-2.95 +77.2% | $-12.96 |
| Total Assets | $231.2M -38.3% | $374.8M -0.4% | $376.3M +27.9% | $294.2M +598.0% | $42.1M |
| Operating Cash Flow | $-88.6M -67.9% | $-52.7M +48.5% | $-102.4M -46.1% | $-70.1M -73.9% | $-40.3M |
Get alerted when GBIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Generation Bio Co. including:
Top Institutional Holders of GBIO
Atlas Venture Life Science Advisors, LLC
$4.7M827,946 shSymBiosis Capital Partners, LLC
$3.8M665,000 shOpaleye Management Inc.
$1.8M310,000 shRENAISSANCE TECHNOLOGIES LLC
$1.6M287,614 shVANGUARD GROUP INC
$1.3M229,833 shSiren, L.L.C.
$1.1M201,419 shUBS Group AG
$935.6K164,716 shMORGAN STANLEY
$916.6K161,378 shMARSHALL WACE, LLP
$796.9K140,294 shYiheng Capital Management, L.P.
$599.4K105,524 sh
| Fund | Value | Shares |
|---|---|---|
| Atlas Venture Life Science Advisors, LLC | $4.7M | 827,946 |
| SymBiosis Capital Partners, LLC | $3.8M | 665,000 |
| Opaleye Management Inc. | $1.8M | 310,000 |
| RENAISSANCE TECHNOLOGIES LLC | $1.6M | 287,614 |
| VANGUARD GROUP INC | $1.3M | 229,833 |
| Siren, L.L.C. | $1.1M | 201,419 |
| UBS Group AG | $935.6K | 164,716 |
| MORGAN STANLEY | $916.6K | 161,378 |
| MARSHALL WACE, LLP | $796.9K | 140,294 |
| Yiheng Capital Management, L.P. | $599.4K | 105,524 |
More Healthcare Companies
View all Healthcare →Put GBIO on your watchlist
Track score changes the day Generation Bio Co. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GBIO a good stock to buy?
13F Pro's AI-powered analysis of Generation Bio Co. (GBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GBIO are available on the GBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own GBIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Generation Bio Co.'s investment landscape.